Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease

Journal of Molecular Medicine

Volumn 86, Issue 4, 2008, Pages 433-442

  Matzner, Ulrich ^a   Matthes, Frank ^a   Weigelt, Cecilia ^c   Andersson, Claes ^c   Eistrup, Carl ^b   Fogh, Jens ^b   Gieselmann, Volkmar ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Zymenex AS   (Denmark)

^c Zymenex A/S   (Sweden)

Author keywords

Arylsulfatase A; Enzyme replacement therapy; Lysosomal storage disease; Metachromatic leukodystrophy; Mouse model

Indexed keywords

CEREBROSIDE SULFATASE; METAZYM; NEUTRALIZING ANTIBODY; RECOMBINANT HUMAN ARYLSULFATASE A; RECOMBINANT HUMAN ARYLSULFATASE A ANTIBODY; SOMATOMEDIN B RECEPTOR; SULFATIDE; UNCLASSIFIED DRUG;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CLEARANCE; CONTROLLED STUDY; CROSS REACTION; DEATH; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPLACEMENT; ENZYME STABILITY; IMMUNE MEDIATED INJURY; IMMUNOLOGICAL TOLERANCE; INHIBITION KINETICS; LETHARGY; LIPID METABOLISM; LOW DRUG DOSE; LYSOSOME STORAGE DISEASE; MACROPHAGE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REDUCTION; SCHWANN CELL;

ANIMALS; ANTIBODIES; BINDING SITES; CELLS, CULTURED; CEREBROSIDE-SULFATASE; GENE THERAPY; HUMANS; KIDNEY; LEUKODYSTROPHY, METACHROMATIC; LYSOSOMAL STORAGE DISEASES; MICE; MICE, KNOCKOUT; RECEPTOR, IGF TYPE 2; RECOMBINANT PROTEINS; SULFOGLYCOSPHINGOLIPIDS;

EID: 42449102542     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-008-0309-3     Document Type: Article

References (28)

1. Matzner U (2005) Therapy of lysosomal storage diseases. In: Saftig P (ed) Lysosomes. Landes Bioscience, Georgetown, USA, pp 112-128
2. de Duve C (1964) From cytases to lysosomes. Fed Proc 23:1045-1049
3. Brady RO (2006) Enzyme replacement for lysosomal diseases. Annu Rev Med 57:283-296
4. Ghosh P, Dahms NM, Kornfeld S (2003) Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4:202-212
5. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE et al (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324:1464-1470
6. Brooks DA, Kakavanos R, Hopwood JJ (2003) Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 9:450-453
7. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM (1999) Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93:2081-2088
8. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66:1589-1595
9. Hunley TE, Corzo T, Dudek M, Kishnani P, Amalfitano A, Chen YT, Richards SM, Phillips JA 3rd, Fogo AB, Tiller GE (2004) Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 114:e532-535
10. Matzner U, Herbst E, Hedayati KK, Lullmann-Rauch R, Wessig C, Schroder S, Eistrup C, Moller C, Fogh J, Gieselmann V (2005) Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet 14:1139-1152
11. Hess B, Saftig P, Hartmann D, Coenen R, Lullmann-Rauch R, Goebel HH, Evers M, von Figura K, D'Hooge R, Nagels G, De Deyn P, Peters C, Gieselmann V (1996) Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc Natl Acad Sci USA 93:14821-14826
12. von Figura K, Gieselmann V, Jaeken J (2001) Metachromatic leukodystrophy. In: Scriver CR, Beaudet WS, Sly D, Valle B, Childs B, Kinzler KW, Vogelstein B (eds) The Metabolic and Molecular Bases of Inherited Disease. Mc Graw-Hill, New York, pp 3695-3724
13. Baum H, Dodgson KS, Spencer B (1959) The assay of arylsulphatases A and B in human urine. Clin Chim Acta 4:453-455
14. Matzner U, Habetha M, Gieselmann V (2000) Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells. Gene Ther 7:805-812
15. Folch J, Lees M, Sloane Stanley GH (1959) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509
16. Matzner U, Matthes F, Herbst E, Lüllmann-Rauch R, Callaerts-Vegh Z, D'Hooge R, Weigelt C, Eistrup C, Fogh J, Gieselmann V (2007) Induction of tolerance to human arylsulfatase A in a mouse model of metachromatic leukodystrophy. Mol Med 13:471-479
17. Saravanan K, Bussow H, Weiler N, Gieselmann V, Franken S (2007) A spontaneously immortalized Schwann cell line to study the molecular aspects of metachromatic leukodystrophy. J Neurosci Methods 161:223-233
18. Klein D, Bussow H, Fewou SN, Gieselmann V (2005) Exocytosis of storage material in a lysosomal disorder. Biochem Biophys Res Commun 327:663-667
19. Xiangrong L, Johnk C, Hartmann D, Schestag F, Kromer W, Gieselmann V (2000) Enzymatic properties, tissue-specific expression, and lysosomal location of two highly homologous rat SULT1C2 sulfotransferases. Biochem Biophys Res Commun 272:242-250
20. Schierau A, Dietz F, Lange H, Schestag F, Parastar A, Gieselmann V (1999) Interaction of arylsulfatase A with UDP-N-acetylglucosamine: lysosomal enzyme-N-acetylglucosamine-1-phosphotransferase. J Biol Chem 274:3651-3658
21. Brooks DA, King BM, Crawley AC, Byers S, Hopwood JJ (1997) Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models. Biochim Biophys Acta 1361:203-216
22. Brooks DA, Hopwood JJ, King BM (1998) Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model. Biochim Biophys Acta 1407:163-172
23. Matzner U, Schestag F, Hartmann D, Lullmann-Rauch R, D'Hooge R, De Deyn PP, Gieselmann V (2001) Bone marrow stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type cells. Hum Gene Ther 12:1021-1033
24. Matzner U, Hartmann D, Lullmann-Rauch R, Coenen R, Rothert F, Mansson JE, Fredman P, D'Hooge R, De Deyn PP, Gieselmann V (2202) Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. Gene Ther 9:53-63
25. Sands MS, Vogler CA, Ohlemiller KK, Roberts MS, Grubb JH, Levy B, Sly WS (2001) Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem 276:43160-43165
26. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65-74
27. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease. Nephrol Dial Transplant 21:345-354
28. Polten A, Fluharty AL, Fluharty CB, Kappler J, von Figura K, Gieselmann V (1991) Molecular basis of different forms of metachromatic leukodystrophy. N Engl J Med 324:18-22